Immunome Statistics
Total Valuation
Immunome has a market cap or net worth of $828.17 million. The enterprise value is $519.57 million.
| Market Cap | 828.17M |
| Enterprise Value | 519.57M |
Important Dates
The last earnings date was Tuesday, May 14, 2024, before market open.
| Earnings Date | May 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunome has 59.97 million shares outstanding. The number of shares has increased by 323.10% in one year.
| Shares Outstanding | 59.97M |
| Shares Change (YoY) | +323.10% |
| Shares Change (QoQ) | +159.75% |
| Owned by Insiders (%) | 16.92% |
| Owned by Institutions (%) | 48.45% |
| Float | 43.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 65.30 |
| Forward PS | 100.65 |
| PB Ratio | 2.90 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 40.97 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.18, with a Debt / Equity ratio of 0.00.
| Current Ratio | 10.18 |
| Quick Ratio | n/a |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -220.50% and return on invested capital (ROIC) is -82.77%.
| Return on Equity (ROE) | -220.50% |
| Return on Assets (ROA) | -153.90% |
| Return on Capital (ROIC) | -82.77% |
| Revenue Per Employee | $230,600 |
| Profits Per Employee | -$4.22M |
| Employee Count | 55 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +143.92% in the last 52 weeks. The beta is 1.88, so Immunome's price volatility has been higher than the market average.
| Beta (1Y) | 1.88 |
| 52-Week Price Change | +143.92% |
| 50-Day Moving Average | 19.07 |
| 200-Day Moving Average | 13.23 |
| Relative Strength Index (RSI) | 30.04 |
| Average Volume (30 Days) | 723,753 |
Short Selling Information
The latest short interest is 5.48 million, so 9.13% of the outstanding shares have been sold short.
| Short Interest | 5.48M |
| Short Previous Month | 3.75M |
| Short % of Shares Out | 9.13% |
| Short % of Float | 12.51% |
| Short Ratio (days to cover) | 6.50 |
Income Statement
In the last 12 months, Immunome had revenue of $12.68 million and -$232.03 million in losses. Loss per share was -$7.55.
| Revenue | 12.68M |
| Gross Profit | 12.68M |
| Operating Income | -237.36M |
| Pretax Income | -232.03M |
| Net Income | -232.03M |
| EBITDA | -231.19M |
| EBIT | -232.03M |
| Loss Per Share | -$7.55 |
Balance Sheet
The company has $309.81 million in cash and $1.21 million in debt, giving a net cash position of $308.60 million or $5.15 per share.
| Cash & Cash Equivalents | 309.81M |
| Total Debt | 1.21M |
| Net Cash | 308.60M |
| Net Cash Per Share | $5.15 |
| Equity / Book Value | 285.57M |
| Book Value Per Share | 4.76 |
| Working Capital | 282.56M |
Cash Flow
In the last 12 months, operating cash flow was -$42.91 million and capital expenditures -$2.89 million, giving a free cash flow of -$45.80 million.
| Operating Cash Flow | -42.91M |
| Capital Expenditures | -2.89M |
| Free Cash Flow | -45.80M |
| FCF Per Share | -$0.89 |
Margins
Gross margin is 100.00%, with operating and profit margins of -1,871.47% and -1,829.44%.
| Gross Margin | 100.00% |
| Operating Margin | -1,871.47% |
| Pretax Margin | -1,829.44% |
| Profit Margin | -1,829.44% |
| EBITDA Margin | -1,822.79% |
| EBIT Margin | -1,829.44% |
| FCF Margin | -361.11% |
Dividends & Yields
Immunome does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -323.10% |
| Shareholder Yield | -323.10% |
| Earnings Yield | -28.02% |
| FCF Yield | -5.53% |
Analyst Forecast
The average price target for Immunome is $30.67, which is 121.76% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $30.67 |
| Price Target Difference | 121.76% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 62.60% |
| EPS Growth Forecast (5Y) | -25.02% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Immunome has an Altman Z-Score of 11.7 and a Piotroski F-Score of 3.
| Altman Z-Score | 11.7 |
| Piotroski F-Score | 3 |